{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:13:16Z","timestamp":1761513196157},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2012,10,6]],"date-time":"2012-10-06T00:00:00Z","timestamp":1349481600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1007\/s00280-012-1990-z","type":"journal-article","created":{"date-parts":[[2012,10,5]],"date-time":"2012-10-05T04:31:50Z","timestamp":1349411510000},"page":"765-782","source":"Crossref","is-referenced-by-count":14,"title":["High-dose etoposide in allogeneic stem cell transplantation"],"prefix":"10.1007","volume":"70","author":[{"given":"\u00d8ystein","family":"Bruserud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e5kon","family":"Reikvam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid Olsnes","family":"Kittang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aymen Bushra","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tor Henrik Anderson","family":"Tvedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malvin","family":"Sjo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberley Joanne","family":"Hatfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,10,6]]},"reference":[{"key":"1990_CR1","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJM198503143121106","volume":"312","author":"PJ O\u2019Dwyer","year":"1985","unstructured":"O\u2019Dwyer PJ, Leyland-Jones B, Alonso MT, Marsoni S, Wittes RE (1985) Etoposide (VP-16-213). Current status of an active anticancer drug. N Engl J Med 312:692\u2013700","journal-title":"N Engl J Med"},{"key":"1990_CR2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF00820727","volume":"18","author":"AH Witterland","year":"1996","unstructured":"Witterland AH, Koks CH, Beijnen JH (1996) Etoposide phosphate, the water soluble prodrug of etoposide. Pharm World Sci 18:163\u2013170","journal-title":"Pharm World Sci"},{"key":"1990_CR3","first-page":"1","volume":"23","author":"L Schacter","year":"1996","unstructured":"Schacter L (1996) Etoposide phosphate: what, why, where, and how? Semin Oncol 23:1\u20137","journal-title":"Semin Oncol"},{"key":"1990_CR4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.canlet.2006.11.005","volume":"252","author":"A Montecucco","year":"2007","unstructured":"Montecucco A, Biamonti G (2007) Cellular response to etoposide treatment. Cancer Lett 252:9\u201318","journal-title":"Cancer Lett"},{"key":"1990_CR5","doi-asserted-by":"crossref","first-page":"29238","DOI":"10.1074\/jbc.271.46.29238","volume":"271","author":"DA Burden","year":"1996","unstructured":"Burden DA, Kingma PS, Froelich-Ammon SJ, Bjornsti MA, Patchan MW, Thompson RB, Osheroff N (1996) Topoisomerase II.etoposide interactions direct the formation of drug-induced enzyme-DNA cleavage complexes. J Biol Chem 271:29238\u201329244","journal-title":"J Biol Chem"},{"key":"1990_CR6","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2174\/1568011033482486","volume":"3","author":"B Gatto","year":"2003","unstructured":"Gatto B, Leo E (2003) Drugs acting on the beta isoform of human topoisomerase II (p180). Curr Med Chem Anticancer Agents 3:173\u2013185","journal-title":"Curr Med Chem Anticancer Agents"},{"key":"1990_CR7","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1038\/sj.onc.1204628","volume":"20","author":"L Jia","year":"2001","unstructured":"Jia L, Patwari Y, Srinivasula SM, Newland AC, Fernandes-Alnemri T, Alnemri ES, Kelsey SM (2001) Bax translocation is crucial for the sensitivity of leukaemic cells to etoposide-induced apoptosis. Oncogene 20:4817\u20134826","journal-title":"Oncogene"},{"key":"1990_CR8","doi-asserted-by":"crossref","first-page":"16547","DOI":"10.1074\/jbc.M110629200","volume":"277","author":"NO Karpinich","year":"2002","unstructured":"Karpinich NO, Tafani M, Rothman RJ, Russo MA, Farber JL (2002) The course of etoposide-induced apoptosis from damage to DNA and p53 activation to mitochondrial release of cytochrome c. J Biol Chem 277:16547\u201316552","journal-title":"J Biol Chem"},{"key":"1990_CR9","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1002\/jcb.20816","volume":"98","author":"A Albihn","year":"2006","unstructured":"Albihn A, Loven J, Ohlsson J, Osorio LM, Henriksson M (2006) c-Myc-dependent etoposide-induced apoptosis involves activation of Bax and caspases, and PKCdelta signaling. J Cell Biochem 98:1597\u20131614","journal-title":"J Cell Biochem"},{"key":"1990_CR10","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3109\/10428199809092687","volume":"28","author":"JF Bishop","year":"1998","unstructured":"Bishop JF, Matthews JP, Young GA, Bradstock K, Lowenthal RM (1998) Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group. Leuk Lymphoma 28:315\u2013327","journal-title":"Leuk Lymphoma"},{"key":"1990_CR11","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1182\/blood.V87.5.1710.1710","volume":"87","author":"JF Bishop","year":"1996","unstructured":"Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D, Bradstock K, Enno A, Wolf MM, Fox R, Cobcroft R, Herrmann R, Van Der Weyden M, Lowenthal RM, Page F, Garson OM, Juneja S (1996) A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 87:1710\u20131717","journal-title":"Blood"},{"key":"1990_CR12","first-page":"1847","volume":"8","author":"WR Vogler","year":"1994","unstructured":"Vogler WR, McCarley DL, Stagg M, Bartolucci AA, Moore J, Martelo O, Omura GA (1994) A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A southeastern cancer study group trial. Leukemia 8:1847\u20131853","journal-title":"Leukemia"},{"key":"1990_CR13","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/BF02985191","volume":"6","author":"A Wahlin","year":"1989","unstructured":"Wahlin A (1989) Amsacrine, cytarabine and etoposide in the treatment of bad prognosis acute myeloid leukemia. Med Oncol Tumor Pharmacother 6:199\u2013205","journal-title":"Med Oncol Tumor Pharmacother"},{"key":"1990_CR14","first-page":"231","volume":"12","author":"O Bruserud","year":"2001","unstructured":"Bruserud O, Foss B, Petersen H (2001) Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L). Eur Cytokine Netw 12:231\u2013238","journal-title":"Eur Cytokine Netw"},{"key":"1990_CR15","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/leu.2009.185","volume":"23","author":"N Hijiya","year":"2009","unstructured":"Hijiya N, Gaynon P, Barry E, Silverman L, Thomson B, Chu R, Cooper T, Kadota R, Rytting M, Steinherz P, Shen V, Jeha S, Abichandani R, Carroll WL (2009) A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia 23:2259\u20132264","journal-title":"Leukemia"},{"key":"1990_CR16","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.3109\/10428194.2012.663915","volume":"53","author":"M Miano","year":"2012","unstructured":"Miano M, Pistorio A, Putti MC, Dufour C, Messina C, Barisone E, Ziino O, Parasole R, Luciani M, Lo Nigro L, Rossi GD, Varotto S, Bertorello N, Petruzziello F, Calvillo M, Micalizzi C (2012) Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients. Leuk Lymphoma 53:1693\u20131698","journal-title":"Leuk Lymphoma"},{"key":"1990_CR17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00277-007-0361-z","volume":"87","author":"M Fiegl","year":"2008","unstructured":"Fiegl M, Zimmermann I, Lorenz I, Hiddemann W, Braess J (2008) In vitro cross-resistance to nucleoside analogues and inhibitors of topoisomerase 1 and 2 in acute myeloid leukemia. Ann Hematol 87:27\u201333","journal-title":"Ann Hematol"},{"key":"1990_CR18","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1046\/j.1365-2141.1998.00593.x","volume":"100","author":"JM Norgaard","year":"1998","unstructured":"Norgaard JM, Bukh A, Langkjer ST, Clausen N, Palshof T, Hokland P (1998) MDR1 gene expression and drug resistance of AML cells. Br J Haematol 100:534\u2013540","journal-title":"Br J Haematol"},{"key":"1990_CR19","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1182\/blood.V80.5.1307.1307","volume":"80","author":"M Chiron","year":"1992","unstructured":"Chiron M, Demur C, Pierson V, Jaffrezou JP, Muller C, Saivin S, Bordier C, Bousquet C, Dastugue N, Laurent G (1992) Sensitivity of fresh acute myeloid leukemia cells to etoposide: relationship with cell growth characteristics and DNA single-strand breaks. Blood 80:1307\u20131315","journal-title":"Blood"},{"key":"1990_CR20","doi-asserted-by":"crossref","first-page":"e12405","DOI":"10.1371\/journal.pone.0012405","volume":"5","author":"DB Rosen","year":"2010","unstructured":"Rosen DB, Putta S, Covey T, Huang YW, Nolan GP, Cesano A, Minden MD, Fantl WJ (2010) Distinct patterns of DNA damage response and apoptosis correlate with Jak\/Stat and PI3kinase response profiles in human acute myelogenous leukemia. PLoS ONE 5:e12405","journal-title":"PLoS ONE"},{"key":"1990_CR21","doi-asserted-by":"crossref","first-page":"7291","DOI":"10.1158\/1078-0432.CCR-09-1222","volume":"15","author":"C Seedhouse","year":"2009","unstructured":"Seedhouse C, Grundy M, Shang S, Ronan J, Pimblett H, Russell N, Pallis M (2009) Impaired S-phase arrest in acute myeloid leukemia cells with a FLT3 internal tandem duplication treated with clofarabine. Clin Cancer Res 15:7291\u20137298","journal-title":"Clin Cancer Res"},{"key":"1990_CR22","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1158\/0008-5472.CAN-09-3950","volume":"70","author":"Y Jin","year":"2010","unstructured":"Jin Y, Lu Z, Ding K, Li J, Du X, Chen C, Sun X, Wu Y, Zhou J, Pan J (2010) Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species. Cancer Res 70:2516\u20132527","journal-title":"Cancer Res"},{"key":"1990_CR23","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/sj.leu.2404980","volume":"22","author":"V Papa","year":"2008","unstructured":"Papa V, Tazzari PL, Chiarini F, Cappellini A, Ricci F, Billi AM, Evangelisti C, Ottaviani E, Martinelli G, Testoni N, McCubrey JA, Martelli AM (2008) Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia 22:147\u2013160","journal-title":"Leukemia"},{"key":"1990_CR24","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood-2004-11-4468","volume":"106","author":"Q Xu","year":"2005","unstructured":"Xu Q, Thompson JE, Carroll M (2005) mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood 106:4261\u20134268","journal-title":"Blood"},{"key":"1990_CR25","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/039463200401700210","volume":"17","author":"R Pietro Di","year":"2004","unstructured":"Di Pietro R, Centurione L, Sabatini N, Bosco D, Sancilio S, Garaci F, Rana R, Cataldi A (2004) Caspase-3 is dually regulated by apoptogenic factors mitochondrial release and by SAPK\/JNK metabolic pathway in leukemic cells exposed to etoposide-ionizing radiation combined treatment. Int J Immunopathol Pharmacol 17:181\u2013190","journal-title":"Int J Immunopathol Pharmacol"},{"key":"1990_CR26","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/jcb.20392","volume":"95","author":"N Sabatini","year":"2005","unstructured":"Sabatini N, Di Giacomo V, Rapino M, Rana R, Garaci G, Cataldi A (2005) JNK\/p53 mediated cell death response in K562 exposed to etoposide-ionizing radiation combined treatment. J Cell Biochem 95:611\u2013619","journal-title":"J Cell Biochem"},{"key":"1990_CR27","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","volume":"371","author":"CH Pui","year":"2008","unstructured":"Pui CH, Robison LL, Look AT (2008) Acute lymphoblastic leukaemia. Lancet 371:1030\u20131043","journal-title":"Lancet"},{"key":"1990_CR28","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1365-2141.2009.07882.x","volume":"147","author":"F Locatelli","year":"2009","unstructured":"Locatelli F, Testi AM, Bernardo ME, Rizzari C, Bertaina A, Merli P, Pession A, Giraldi E, Parasole R, Barberi W, Zecca M (2009) Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory\/multiple relapsed acute lymphoblastic leukaemia. Br J Haematol 147:371\u2013378","journal-title":"Br J Haematol"},{"key":"1990_CR29","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1365-2141.2010.08236.x","volume":"150","author":"LA Commander","year":"2010","unstructured":"Commander LA, Seif AE, Insogna IG, Rheingold SR (2010) Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed\/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma. Br J Haematol 150:345\u2013351","journal-title":"Br J Haematol"},{"key":"1990_CR30","first-page":"1701","volume":"90","author":"MA Horstmann","year":"2005","unstructured":"Horstmann MA, Hassenpflug WA, zur Stadt U, Escherich G, Janka G, Kabisch H (2005) Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children. Haematologica 90:1701\u20131703","journal-title":"Haematologica"},{"key":"1990_CR31","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/sj.thj.6200353","volume":"5","author":"O Reman","year":"2004","unstructured":"Reman O, Buzyn A, Lheritier V, Huguet F, Kuentz M, Stamatoullas A, Delannoy A, Fegueux N, Miclea JM, Boiron JM, Vernant JP, Gardin C, Hacini M, Georges M, Fiere D, Thomas X (2004) Rescue therapy combining intermediate-dose cytarabine with amsacrine and etoposide in relapsed adult acute lymphoblastic leukemia. Hematol J 5:123\u2013129","journal-title":"Hematol J"},{"key":"1990_CR32","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1182\/blood-2003-12-4426","volume":"104","author":"BM Frost","year":"2004","unstructured":"Frost BM, Forestier E, Gustafsson G, Nygren P, Hellebostad M, Jonsson OG, Kanerva J, Schmiegelow K, Larsson R, Lonnerholm G (2004) Translocation t(12;21) is related to in vitro cellular drug sensitivity to doxorubicin and etoposide in childhood acute lymphoblastic leukemia. Blood 104:2452\u20132457","journal-title":"Blood"},{"key":"1990_CR33","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1046\/j.1365-2141.2003.04442.x","volume":"122","author":"BM Frost","year":"2003","unstructured":"Frost BM, Nygren P, Gustafsson G, Forestier E, Jonsson OG, Kanerva J, Nygaard R, Schmiegelow K, Larsson R, Lonnerholm G (2003) Increased in vitro cellular drug resistance is related to poor outcome in high-risk childhood acute lymphoblastic leukaemia. Br J Haematol 122:376\u2013385","journal-title":"Br J Haematol"},{"key":"1990_CR34","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/BF02982795","volume":"76","author":"T Hongo","year":"2002","unstructured":"Hongo T, Okada S, Inoue N, Yamada S, Yajima S, Watanabe C, Fujii Y, Horikoshi Y (2002) Two groups of Philadelphia chromosome-positive childhood acute lymphoblastic leukemia classified by pretreatment multidrug sensitivity or resistance in in vitro testing. Int J Hematol 76:251\u2013259","journal-title":"Int J Hematol"},{"key":"1990_CR35","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1182\/blood.V89.8.2959","volume":"89","author":"T Hongo","year":"1997","unstructured":"Hongo T, Yajima S, Sakurai M, Horikoshi Y, Hanada R (1997) In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. Blood 89:2959\u20132965","journal-title":"Blood"},{"key":"1990_CR36","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa033513","volume":"351","author":"A Holleman","year":"2004","unstructured":"Holleman A, Cheok MH, den Boer ML, Yang W, Veerman AJ, Kazemier KM, Pei D, Cheng C, Pui CH, Relling MV, Janka-Schaub GE, Pieters R, Evans WE (2004) Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 351:533\u2013542","journal-title":"N Engl J Med"},{"key":"1990_CR37","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1756-9966-30-112","volume":"30","author":"JA Rosales-Avina","year":"2011","unstructured":"Rosales-Avina JA, Torres-Flores J, Aguilar-Lemarroy A, Gurrola-Diaz C, Hernandez-Flores G, Ortiz-Lazareno PC, Lerma-Diaz JM, de Celis R, Gonzalez-Ramella O, Barrera-Chaires E, Bravo-Cuellar A, Jave-Suarez LF (2011) MEIS1, PREP1, and PBX4 are differentially expressed in acute lymphoblastic leukemia: association of MEIS1 expression with higher proliferation and chemotherapy resistance. J Exp Clin Cancer Res 30:112","journal-title":"J Exp Clin Cancer Res"},{"key":"1990_CR38","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3324\/haematol.2011.049593","volume":"97","author":"SH Thathia","year":"2012","unstructured":"Thathia SH, Ferguson S, Gautrey HE, van Otterdijk SD, Hili M, Rand V, Moorman AV, Meyer S, Brown R, Strathdee G (2012) Epigenetic inactivation of TWIST2 in acute lymphoblastic leukemia modulates proliferation, cell survival and chemosensitivity. Haematologica 97:371\u2013378","journal-title":"Haematologica"},{"key":"1990_CR39","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.biopha.2009.09.005","volume":"64","author":"LS Thiago","year":"2010","unstructured":"Thiago LS, Costa ES, Lopes DV, Otazu IB, Nowill AE, Mendes FA, Portilho DM, Abreu JG, Mermelstein CS, Orfao A, Rossi MI, Borojevic R (2010) The Wnt signaling pathway regulates Nalm-16 b-cell precursor acute lymphoblastic leukemic cell line survival and etoposide resistance. Biomed Pharmacother 64:63\u201372","journal-title":"Biomed Pharmacother"},{"key":"1990_CR40","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/carcin\/bgm294","volume":"29","author":"KT Leung","year":"2008","unstructured":"Leung KT, Li KK, Sun SS, Chan PK, Ooi VE, Chiu LC (2008) Activation of the JNK pathway promotes phosphorylation and degradation of BimEL\u2014a novel mechanism of chemoresistance in T-cell acute lymphoblastic leukemia. Carcinogenesis 29:544\u2013551","journal-title":"Carcinogenesis"},{"key":"1990_CR41","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V81.2.319.319","volume":"81","author":"NJ Chao","year":"1993","unstructured":"Chao NJ, Stein AS, Long GD, Negrin RS, Amylon MD, Wong RM, Forman SJ, Blume KG (1993) Busulfan\/etoposide\u2013initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia. Blood 81:319\u2013323","journal-title":"Blood"},{"key":"1990_CR42","first-page":"819","volume":"70","author":"HM Lazarus","year":"1986","unstructured":"Lazarus HM, Creger RJ, Diaz D (1986) Simple method for the administration of high-dose etoposide during autologous bone marrow transplantation. Cancer Treat Rep 70:819\u2013820","journal-title":"Cancer Treat Rep"},{"key":"1990_CR43","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s002800050498","volume":"38","author":"W Kreis","year":"1996","unstructured":"Kreis W, Budman DR, Vinciguerra V, Hock K, Baer J, Ingram R, Schacter LP, Fields SZ (1996) Pharmacokinetic evaluation of high-dose etoposide phosphate after a 2-hour infusion in patients with solid tumors. Cancer Chemother Pharmacol 38:378\u2013384","journal-title":"Cancer Chemother Pharmacol"},{"key":"1990_CR44","first-page":"851","volume":"18","author":"SZ Fields","year":"1996","unstructured":"Fields SZ, Budman DR, Young RR, Kreis W, Ingram R, Schulman P, Cherny RC, Wright J, Behr J, Snow C, Schacter LP (1996) Phase I study of high-dose etoposide phosphate in man. Bone Marrow Transplant 18:851\u2013856","journal-title":"Bone Marrow Transplant"},{"key":"1990_CR45","first-page":"8","volume":"23","author":"DR Budman","year":"1996","unstructured":"Budman DR (1996) Early studies of etoposide phosphate, a water-soluble prodrug. Semin Oncol 23:8\u201314","journal-title":"Semin Oncol"},{"key":"1990_CR46","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/1097-0142(19910101)67:1+<292::AID-CNCR2820671314>3.0.CO;2-7","volume":"67","author":"RH Herzig","year":"1991","unstructured":"Herzig RH (1991) High-dose etoposide and marrow transplantation. Cancer 67:292\u2013298","journal-title":"Cancer"},{"key":"1990_CR47","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1200\/JCO.1983.1.11.701","volume":"1","author":"SN Wolff","year":"1983","unstructured":"Wolff SN, Fer MF, McKay CM, Hande KR, Hainsworth JD, Greco FA (1983) High-dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: a phase I study. J Clin Oncol 1:701\u2013705","journal-title":"J Clin Oncol"},{"key":"1990_CR48","unstructured":"Bensinger WI (2004) High-dose preparatory regimens. In: Appelbaum FR, Forman SJ, Negrin RS, Blume KG (eds) Thomas` hematopoietic cell transplantation, pp 316\u2013322"},{"key":"1990_CR49","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood.V76.3.473.473","volume":"76","author":"RA Brown","year":"1990","unstructured":"Brown RA, Herzig RH, Wolff SN, Frei-Lahr D, Pineiro L, Bolwell BJ, Lowder JN, Harden EA, Hande KR, Herzig GP (1990) High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy. Blood 76:473\u2013479","journal-title":"Blood"},{"key":"1990_CR50","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1399-3046.2010.01418.x","volume":"15","author":"M Chrzanowska","year":"2011","unstructured":"Chrzanowska M, Sobiak J, Grund G, Wachowiak J (2011) Pharmacokinetics of high-dose etoposide administered in combination with fractionated total-body irradiation as conditioning for allogeneic hematopoietic stem cell transplantation in children with acute lymphoblastic leukemia. Pediatr Transpl 15:96\u2013102","journal-title":"Pediatr Transpl"},{"key":"1990_CR51","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/BF00685951","volume":"29","author":"P Kohl","year":"1992","unstructured":"Kohl P, Koppler H, Schmidt L, Fritsch HW, Holz J, Pfluger KH, Jungclas H (1992) Pharmacokinetics of high-dose etoposide after short-term infusion. Cancer Chemother Pharmacol 29:316\u2013320","journal-title":"Cancer Chemother Pharmacol"},{"key":"1990_CR52","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/clpt.1988.73","volume":"43","author":"EM Newman","year":"1988","unstructured":"Newman EM, Doroshow JH, Forman SJ, Blume KG (1988) Pharmacokinetics of high-dose etoposide. Clin Pharmacol Ther 43:561\u2013564","journal-title":"Clin Pharmacol Ther"},{"key":"1990_CR53","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1200\/JCO.1986.4.11.1690","volume":"4","author":"SG Arbuck","year":"1986","unstructured":"Arbuck SG, Douglass HO, Crom WR, Goodwin P, Silk Y, Cooper C, Evans WE (1986) Etoposide pharmacokinetics in patients with normal and abnormal organ function. J Clin Oncol 4:1690\u20131695","journal-title":"J Clin Oncol"},{"key":"1990_CR54","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1517\/14740338.4.2.219","volume":"4","author":"K Seiter","year":"2005","unstructured":"Seiter K (2005) Toxicity of the topoisomerase II inhibitors. Expert Opin Drug Saf 4:219\u2013234","journal-title":"Expert Opin Drug Saf"},{"key":"1990_CR55","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1182\/blood.V69.4.1015.1015","volume":"69","author":"KG Blume","year":"1987","unstructured":"Blume KG, Forman SJ, O\u2019Donnell MR, Doroshow JH, Krance RA, Nademanee AP, Snyder DS, Schmidt GM, Fahey JL, Metter GE et al (1987) Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies. Blood 69:1015\u20131020","journal-title":"Blood"},{"key":"1990_CR56","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1182\/blood-2008-03-143115","volume":"112","author":"GG Laport","year":"2008","unstructured":"Laport GG, Alvarnas JC, Palmer JM, Snyder DS, Slovak ML, Cherry AM, Wong RM, Negrin RS, Blume KG, Forman SJ (2008) Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen. Blood 112:903\u2013909","journal-title":"Blood"},{"key":"1990_CR57","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1182\/blood.V72.5.1567.1567","volume":"72","author":"N Schmitz","year":"1988","unstructured":"Schmitz N, Gassmann W, Rister M, Johannson W, Suttorp M, Brix F, Holthuis JJ, Heit W, Hertenstein B, Schaub J et al (1988) Fractionated total body irradiation and high-dose VP 16\u2013213 followed by allogeneic bone marrow transplantation in advanced leukemias. Blood 72:1567\u20131573","journal-title":"Blood"},{"key":"1990_CR58","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood.V82.9.2920.2920","volume":"82","author":"DS Snyder","year":"1993","unstructured":"Snyder DS, Chao NJ, Amylon MD, Taguchi J, Long GD, Negrin RS, Nademanee AP, O\u2019Donnell MR, Schmidt GM, Stein AS et al (1993) Fractionated total body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 99 patients with acute leukemia in first complete remission. Blood 82:2920\u20132928","journal-title":"Blood"},{"key":"1990_CR59","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1182\/blood.V81.8.2187.2187","volume":"81","author":"KG Blume","year":"1993","unstructured":"Blume KG, Kopecky KJ, Henslee-Downey JP, Forman SJ, Stiff PJ, LeMaistre CF, Appelbaum FR (1993) A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a southwest oncology group study. Blood 81:2187\u20132193","journal-title":"Blood"},{"key":"1990_CR60","doi-asserted-by":"crossref","unstructured":"Worthington HV, Clarkson JE, Eden OB (2007) Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev:CD000978","DOI":"10.1002\/14651858.CD000978.pub3"},{"key":"1990_CR61","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ijom.2011.10.011","volume":"41","author":"A Rodriguez-Caballero","year":"2012","unstructured":"Rodriguez-Caballero A, Torres-Lagares D, Robles-Garcia M, Pachon-Ibanez J, Gonzalez-Padilla D, Gutierrez-Perez JL (2012) Cancer treatment-induced oral mucositis: a critical review. Int J Oral Maxillofac Surg 41:225\u2013238","journal-title":"Int J Oral Maxillofac Surg"},{"key":"1990_CR62","doi-asserted-by":"crossref","first-page":"5186","DOI":"10.1200\/JCO.2005.02.8340","volume":"24","author":"PJ Stiff","year":"2006","unstructured":"Stiff PJ, Emmanouilides C, Bensinger WI, Gentile T, Blazar B, Shea TC, Lu J, Isitt J, Cesano A, Spielberger R (2006) Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J Clin Oncol 24:5186\u20135193","journal-title":"J Clin Oncol"},{"key":"1990_CR63","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.2009.25.1983","volume":"28","author":"G Tallen","year":"2010","unstructured":"Tallen G, Ratei R, Mann G, Kaspers G, Niggli F, Karachunsky A, Ebell W, Escherich G, Schrappe M, Klingebiel T, Fengler R, Henze G, von Stackelberg A (2010) Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol 28:2339\u20132347","journal-title":"J Clin Oncol"},{"key":"1990_CR64","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.bbmt.2005.12.029","volume":"12","author":"DI Marks","year":"2006","unstructured":"Marks DI, Forman SJ, Blume KG, Perez WS, Weisdorf DJ, Keating A, Gale RP, Cairo MS, Copelan EA, Horan JT, Lazarus HM, Litzow MR, McCarthy PL, Schultz KR, Smith DD, Trigg ME, Zhang MJ, Horowitz MM (2006) A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission. Biol Blood Marrow Transplant 12:438\u2013453","journal-title":"Biol Blood Marrow Transplant"},{"key":"1990_CR65","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/bmt.2009.365","volume":"45","author":"R Hoyt","year":"2010","unstructured":"Hoyt R, Ritchie DS, Wirth A, Szer J, Grigg AP (2010) Etoposide induces more severe mucositis than CY when added to TBI as conditioning in allograft recipients receiving CsA and MTX. Bone Marrow Transplant 45:1457\u20131462","journal-title":"Bone Marrow Transplant"},{"key":"1990_CR66","first-page":"324","volume":"3","author":"GD Long","year":"1997","unstructured":"Long GD, Amylon MD, Stockerl-Goldstein KE, Negrin RS, Chao NJ, Hu WW, Nademanee AP, Snyder DS, Hoppe RT, Vora N, Wong R, Niland J, Reichardt VL, Forman SJ, Blume KG (1997) Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies. Biol Blood Marrow Transplant 3:324\u2013330","journal-title":"Biol Blood Marrow Transplant"},{"key":"1990_CR67","first-page":"131","volume":"18","author":"MW Brunvand","year":"1996","unstructured":"Brunvand MW, Bensinger WI, Soll E, Weaver CH, Rowley SD, Appelbaum FR, Lilleby K, Clift RA, Gooley TA, Press OW, Fefer A, Storb R, Sanders JE, Martin PL, Chauncey T, Maziarz RT, Zuckerman N, Montgomery P, Dorn R, Weiden PL, Demirer T, Holmberg LA, Schiffman K, McSweeney PA, Buckner CD et al (1996) High-dose fractionated total-body irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: comparison of autologous bone marrow and peripheral blood stem cells. Bone Marrow Transplant 18:131\u2013141","journal-title":"Bone Marrow Transplant"},{"key":"1990_CR68","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1200\/JCO.1994.12.12.2552","volume":"12","author":"SJ Horning","year":"1994","unstructured":"Horning SJ, Negrin RS, Chao JC, Long GD, Hoppe RT, Blume KG (1994) Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin\u2019s disease and non-Hodgkin\u2019s lymphoma. J Clin Oncol 12:2552\u20132558","journal-title":"J Clin Oncol"},{"key":"1990_CR69","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1200\/JCO.1994.12.12.2559","volume":"12","author":"CH Weaver","year":"1994","unstructured":"Weaver CH, Petersen FB, Appelbaum FR, Bensinger WI, Press O, Martin P, Sandmaier B, Deeg HJ, Hansen JA, Brunvand M et al (1994) High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma. J Clin Oncol 12:2559\u20132566","journal-title":"J Clin Oncol"},{"key":"1990_CR70","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/blood.V89.3.801","volume":"89","author":"SJ Horning","year":"1997","unstructured":"Horning SJ, Chao NJ, Negrin RS, Hoppe RT, Long GD, Hu WW, Wong RM, Brown BW, Blume KG (1997) High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin\u2019s disease: analysis of the Stanford University results and prognostic indices. Blood 89:801\u2013813","journal-title":"Blood"},{"key":"1990_CR71","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1182\/blood-2003-10-3560","volume":"104","author":"M Hunault","year":"2004","unstructured":"Hunault M, Harousseau JL, Delain M, Truchan-Graczyk M, Cahn JY, Witz F, Lamy T, Pignon B, Jouet JP, Garidi R, Caillot D, Berthou C, Guyotat D, Sadoun A, Sotto JJ, Lioure B, Casassus P, Solal-Celigny P, Stalnikiewicz L, Audhuy B, Blanchet O, Baranger L, Bene MC, Ifrah N (2004) Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood 104:3028\u20133037","journal-title":"Blood"},{"key":"1990_CR72","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s12185-011-0944-2","volume":"94","author":"A Shigematsu","year":"2011","unstructured":"Shigematsu A, Tanaka J, Suzuki R, Atsuta Y, Kawase T, Ito YM, Yamashita T, Fukuda T, Kumano K, Iwato K, Yoshiba F, Kanamori H, Kobayashi N, Fukuhara T, Morishima Y, Imamura M (2011) Outcome of medium-dose VP-16\/CY\/TBI superior to CY\/TBI as a conditioning regimen for allogeneic stem cell transplantation in adult patients with acute lymphoblastic leukemia. Int J Hematol 94:463\u2013471","journal-title":"Int J Hematol"},{"key":"1990_CR73","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.bbmt.2008.02.018","volume":"14","author":"A Shigematsu","year":"2008","unstructured":"Shigematsu A, Kondo T, Yamamoto S, Sugita J, Onozawa M, Kahata K, Endo T, Shiratori S, Ota S, Obara M, Wakasa K, Takahata M, Takeda Y, Tanaka J, Hashino S, Nishio M, Koike T, Asaka M, Imamura M (2008) Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia. Biol Blood Marrow Transplant 14:568\u2013575","journal-title":"Biol Blood Marrow Transplant"},{"key":"1990_CR74","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood.V81.2.311.311","volume":"81","author":"CA Linker","year":"1993","unstructured":"Linker CA, Ries CA, Damon LE, Rugo HS, Wolf JL (1993) Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen. Blood 81:311\u2013318","journal-title":"Blood"},{"key":"1990_CR75","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/sj.bmt.1704867","volume":"35","author":"SS Farag","year":"2005","unstructured":"Farag SS, Bolwell BJ, Elder PJ, Kalaycio M, Lin T, Pohlman B, Penza S, Marcucci G, Blum W, Sobecks R, Avalos BR, Byrd JC, Copelan E (2005) High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia. Bone Marrow Transplant 35:653\u2013661","journal-title":"Bone Marrow Transplant"},{"key":"1990_CR76","unstructured":"Crilley P, Lazarus H, Topolsky D, Ciobanu N, Creger RJ, Fox RM, Bulova SI, Shina DC, Gucalp R, Cooper BW et al (1993) Comparison of preparative transplantation regimens using carmustine\/etoposide\/cisplatin or busulfan\/etoposide\/cyclophosphamide in lymphoid malignancies. Semin Oncol 20:50\u201354; quiz 55"},{"key":"1990_CR77","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/jcbfm.1995.45","volume":"15","author":"P Crilley","year":"1995","unstructured":"Crilley P, Topolsky D, Styler MJ, Bernstein E, Resnick K, Mullaney R, Bulova S, Brodsky I, Marks DI (1995) Extramedullary toxicity of a conditioning regimen containing busulphan, cyclophosphamide and etoposide in 84 patients undergoing autologous and allogenic bone marrow transplantation. Bone Marrow Transplant 15:361\u2013365","journal-title":"Bone Marrow Transplant"},{"key":"1990_CR78","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1159\/000046569","volume":"105","author":"PJ Tutschka","year":"2001","unstructured":"Tutschka PJ, Bilgrami SA, Feingold JM, Edwards RL, Bona RD, Naqvi B, Clive J (2001) Cytoreduction and stem cell mobilization with a regimen of paclitaxel, etoposide and cyclophosphamide followed by autologous transplantation using a preparative regimen of busulfan, etoposide and cyclophosphamide for patients with advanced lymphoma. Acta Haematol 105:222\u2013232","journal-title":"Acta Haematol"},{"key":"1990_CR79","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/leu.2010.319","volume":"25","author":"SS Farag","year":"2011","unstructured":"Farag SS, Wood LL, Schwartz JE, Srivastava S, Nelson RP Jr, Robertson MJ, Abonour R, Secrest A, Cox E, Baute J, Sullivan C, Kane K, Jones DR (2011) Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia. Leukemia 25:599\u2013605","journal-title":"Leukemia"},{"key":"1990_CR80","doi-asserted-by":"crossref","first-page":"4258","DOI":"10.1182\/blood-2011-06-358010","volume":"118","author":"J Magenau","year":"2011","unstructured":"Magenau J, Tobai H, Pawarode A, Braun T, Peres E, Reddy P, Kitko C, Choi S, Yanik G, Frame D, Harris A, Erba H, Kujawski L, Elenitoba-Johnson K, Sanks J, Jones D, Paczesny S, Ferrara J, Levine J, Mineishi S (2011) Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies. Blood 118:4258\u20134264","journal-title":"Blood"},{"key":"1990_CR81","doi-asserted-by":"crossref","unstructured":"Andersson BS, Gajewski J, Donato M, Giralt S, Gian V, Wingard J, Tarantolo S, Fernandez H, Hu WW, Blume K, Kashyap A, Forman SJ, Champlin RE (2000) Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy). Bone Marrow Transplant 25(Suppl 2):S35\u2013S38","DOI":"10.1038\/sj.bmt.1702351"},{"key":"1990_CR82","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.bbmt.2010.10.016","volume":"17","author":"S Srivastava","year":"2011","unstructured":"Srivastava S, Jones D, Wood LL, Schwartz JE, Nelson RP Jr, Abonour R, Secrest A, Cox E, Baute J, Sullivan C, Kane K, Robertson MJ, Farag SS (2011) A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma. Biol Blood Marrow Transplant 17:987\u2013994","journal-title":"Biol Blood Marrow Transplant"},{"key":"1990_CR83","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1200\/JCO.1995.13.3.596","volume":"13","author":"T Demirer","year":"1995","unstructured":"Demirer T, Weaver CH, Buckner CD, Petersen FB, Bensinger WI, Sanders J, Clift RA, Lilleby K, Anasetti C, Martin P et al (1995) High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy. J Clin Oncol 13:596\u2013602","journal-title":"J Clin Oncol"},{"key":"1990_CR84","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1182\/blood.V81.5.1137.1137","volume":"81","author":"R Chopra","year":"1993","unstructured":"Chopra R, McMillan AK, Linch DC, Yuklea S, Taghipour G, Pearce R, Patterson KG, Goldstone AH (1993) The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin\u2019s disease. A single-center eight-year study of 155 patients. Blood 81:1137\u20131145","journal-title":"Blood"},{"key":"1990_CR85","first-page":"56","volume":"12","author":"PJ Stiff","year":"1998","unstructured":"Stiff PJ (1998) Blood and marrow transplantation in relapsed or refractory non-Hodgkin\u2019s lymphoma. Oncology 12:56\u201362","journal-title":"Oncology"},{"key":"1990_CR86","first-page":"335","volume":"17","author":"S Ager","year":"1996","unstructured":"Ager S, Mahendra P, Richards EM, Bass G, Baglin TP, Marcus RE (1996) High-dose carmustine, etoposide and melphalan (BEM) with autologous stem cell transplantation: a dose-toxicity study. Bone Marrow Transplant 17:335\u2013340","journal-title":"Bone Marrow Transplant"},{"key":"1990_CR87","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1200\/JCO.1992.10.11.1682","volume":"10","author":"HM Lazarus","year":"1992","unstructured":"Lazarus HM, Crilley P, Ciobanu N, Creger RJ, Fox RM, Shina DC, Bulova SI, Gucalp R, Cooper BW, Topolsky D et al (1992) High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma. J Clin Oncol 10:1682\u20131689","journal-title":"J Clin Oncol"},{"key":"1990_CR88","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/1097-0142(19950315)75:6<1354::AID-CNCR2820750618>3.0.CO;2-M","volume":"75","author":"NJ Chao","year":"1995","unstructured":"Chao NJ, Kastrissios H, Long GD, Negrin RS, Horning SJ, Wong RM, Blaschke TF, Blume KG (1995) A new preparatory regimen for autologous bone marrow transplantation for patients with lymphoma. Cancer 75:1354\u20131359","journal-title":"Cancer"},{"key":"1990_CR89","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1002\/1097-0142(19940315)73:6<1678::AID-CNCR2820730621>3.0.CO;2-U","volume":"73","author":"G Somlo","year":"1994","unstructured":"Somlo G, Doroshow JH, Forman SJ, Leong LA, Margolin KA, Morgan RJ Jr, Raschko JW, Akman SA, Ahn C, Nagasawa S et al (1994) High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of hope bone marrow oncology team. Cancer 73:1678\u20131685","journal-title":"Cancer"},{"key":"1990_CR90","first-page":"59","volume":"20","author":"KK Fields","year":"1993","unstructured":"Fields KK, Elfenbein GJ, Perkins JB, Hiemenz JW, Janssen WE, Zorsky PE, Ballester OF, Kronish LE, Foody MC (1993) Two novel high-dose treatment regimens for metastatic breast cancer\u2013ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicities. Semin Oncol 20:59\u201366","journal-title":"Semin Oncol"},{"key":"1990_CR91","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1200\/JCO.1992.10.11.1712","volume":"10","author":"WH Wilson","year":"1992","unstructured":"Wilson WH, Jain V, Bryant G, Cowan KH, Carter C, Cottler-Fox M, Goldspiel B, Steinberg SM, Longo DL, Wittes RE (1992) Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors. J Clin Oncol 10:1712\u20131722","journal-title":"J Clin Oncol"},{"key":"1990_CR92","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s12185-011-0919-3","volume":"94","author":"K Arita","year":"2011","unstructured":"Arita K, Kondo T, Sugita J, Shigematsu A, Shiratori S, Wakasa K, Yasumoto A, Ibata M, Shono Y, Kikuchi M, Goto H, Takeda Y, Takahata M, Kato N, Nishio M, Ota S, Tanaka J, Imamura M (2011) Sequential chemotherapy and myeloablative allogeneic hematopoietic stem cell transplantation for refractory acute lymphoblastic leukemia. Int J Hematol 94:291\u2013295","journal-title":"Int J Hematol"},{"key":"1990_CR93","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.bbmt.2009.06.017","volume":"15","author":"QF Liu","year":"2009","unstructured":"Liu QF, Fan ZP, Zhang Y, Jiang ZJ, Wang CY, Xu D, Sun J, Xiao Y, Tan H (2009) Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia. Biol Blood Marrow Transplant 15:1376\u20131385","journal-title":"Biol Blood Marrow Transplant"},{"key":"1990_CR94","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1365-2141.2010.08337.x","volume":"152","author":"RM Sobecks","year":"2011","unstructured":"Sobecks RM, Copelan E, Kalaycio M, Askar M, Rybicki L, Serafino S, Serafin M, Macklis R, Dean R, Pohlman B, Andresen S, Bolwell BJ (2011) Multiple unit umbilical cord blood transplantation with total body irradiation, etoposide and antithymocyte globulin for adult haematological malignancy patients. Br J Haematol 152:116\u2013119","journal-title":"Br J Haematol"},{"key":"1990_CR95","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/sj.bmt.1705142","volume":"36","author":"R Vibhakar","year":"2005","unstructured":"Vibhakar R, Radhi M, Rumelhart S, Tatman D, Goldman F (2005) Successful unrelated umbilical cord blood transplantation in children with Shwachman-Diamond syndrome. Bone Marrow Transplant 36:855\u2013861","journal-title":"Bone Marrow Transplant"},{"key":"1990_CR96","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejca.2007.09.019","volume":"44","author":"A Borgmann","year":"2008","unstructured":"Borgmann A, Zinn C, Hartmann R, Herold R, Kaatsch P, Escherich G, Moricke A, Henze G, von Stackelberg A (2008) Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood. Eur J Cancer 44:257\u2013268","journal-title":"Eur J Cancer"},{"key":"1990_CR97","doi-asserted-by":"crossref","first-page":"666","DOI":"10.2174\/156800908786733496","volume":"8","author":"O Bruserud","year":"2008","unstructured":"Bruserud O, Ersvaer E, Olsnes A, Gjertsen BT (2008) Anticancer immunotherapy in combination with proapoptotic therapy. Curr Cancer Drug Targets 8:666\u2013675","journal-title":"Curr Cancer Drug Targets"},{"issue":"Suppl 1","key":"1990_CR98","first-page":"S131","volume":"14","author":"AM Olsnes","year":"2009","unstructured":"Olsnes AM, Hatfield KJ, Bruserud O (2009) The chemokine system and its contribution to leukemogenesis and treatment responsiveness in patients with acute myeloid leukemia. J BUON 14(Suppl 1):S131\u2013S140","journal-title":"J BUON"},{"key":"1990_CR99","doi-asserted-by":"crossref","unstructured":"Liseth K, Ersvaer E, Hervig T, Bruserud O (2010) Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience. J Biomed Biotechnol 2010:692097","DOI":"10.1155\/2010\/692097"},{"key":"1990_CR100","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/82_2010_18","volume":"341","author":"O Bruserud","year":"2010","unstructured":"Bruserud O, Kittang AO (2010) The chemokine system in experimental and clinical hematology. Curr Top Microbiol Immunol 341:3\u201312","journal-title":"Curr Top Microbiol Immunol"},{"key":"1990_CR101","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1002\/(SICI)1521-4141(199910)29:10<3225::AID-IMMU3225>3.0.CO;2-0","volume":"29","author":"H Muhl","year":"1999","unstructured":"Muhl H, Nold M, Chang JH, Frank S, Eberhardt W, Pfeilschifter J (1999) Expression and release of chemokines associated with apoptotic cell death in human promonocytic U937 cells and peripheral blood mononuclear cells. Eur J Immunol 29:3225\u20133235","journal-title":"Eur J Immunol"},{"key":"1990_CR102","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s002800100357","volume":"48","author":"LM Slater","year":"2001","unstructured":"Slater LM, Stupecky M, Sweet P, Osann K, Eklof A, Arquilla ER (2001) Etoposide induction of tumor immunity in Lewis lung cancer. Cancer Chemother Pharmacol 48:327\u2013332","journal-title":"Cancer Chemother Pharmacol"},{"key":"1990_CR103","doi-asserted-by":"crossref","first-page":"e32542","DOI":"10.1371\/journal.pone.0032542","volume":"7","author":"S Wan","year":"2012","unstructured":"Wan S, Pestka S, Jubin RG, Lyu YL, Tsai YC, Liu LF (2012) Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells. PLoS ONE 7:e32542","journal-title":"PLoS ONE"},{"key":"1990_CR104","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0027-5107(98)00239-5","volume":"423","author":"K Hogstrand","year":"1999","unstructured":"Hogstrand K, Bohme J (1999) DNA damage caused by etoposide and gamma-irradiation induces gene conversion of the MHC in a mouse non-germline testis cell line. Mutat Res 423:155\u2013169","journal-title":"Mutat Res"},{"key":"1990_CR105","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/cyto.a.21132","volume":"79","author":"C Winzler","year":"2011","unstructured":"Winzler C, Fantinato M, Giordan M, Calore E, Basso G, Messina C (2011) CD4(+) T regulatory cells are more resistant to DNA damage compared to CD4(+) T effector cells as revealed by flow cytometric analysis. Cytometry Part A 79:903\u2013911","journal-title":"Cytometry Part A"},{"key":"1990_CR106","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1182\/blood.V72.5.1574.1574","volume":"72","author":"W Gassmann","year":"1988","unstructured":"Gassmann W, Uharek L, Wottge HU, Schmitz N, Loffler H, Mueller-Ruchholtz W (1988) Comparison of cyclophosphamide, cytarabine, and etoposide as immunosuppressive agents before allogeneic bone marrow transplantation. Blood 72:1574\u20131579","journal-title":"Blood"},{"key":"1990_CR107","first-page":"259","volume":"6","author":"M Crump","year":"1990","unstructured":"Crump M, Brandwein JM, Scott JG, Sutcliffe SB, Keating A (1990) Acute transient parotitis after high dose etoposide and autologous bone marrow transplantation. Bone Marrow Transplant 6:259\u2013261","journal-title":"Bone Marrow Transplant"},{"key":"1990_CR108","unstructured":"Blume K, Buckner D (1995) Workshop: high dose etoposide containing regimens. BMT 15:S207\u2013S212"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-012-1990-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-012-1990-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-012-1990-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T00:41:11Z","timestamp":1643503271000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-012-1990-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,6]]},"references-count":108,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["1990"],"URL":"https:\/\/doi.org\/10.1007\/s00280-012-1990-z","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,6]]}}}